Jean-Pol Detiffe

🚀Your Partner for Clinical Innovation 🚀 Are you looking for an innovative, expert, reliable and responsive partner for your clinical trials ? At Biophysium, we turn your 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥-𝐩𝐡𝐚𝐬𝐞 projects into successes. We offer a full range of services to evaluate the efficacy and safety of 𝐝𝐫𝐮𝐠𝐬, 𝐧𝐮𝐭𝐫𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 or 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐢𝐜𝐞𝐬. Our experienced team is with you every step of the way, conducting on-site clinical studies while combining 𝐜𝐫𝐨𝐬𝐬-𝐬𝐞𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐚𝐧𝐚𝐥𝐲𝐬𝐞𝐬 ( proteomics, metabolomics, cardiac and vascular ultrasound, blood tests..), all in a flexible and responsive environment. 🔬 Thanks to our 𝐡𝐮𝐦𝐚𝐧 𝐬𝐜𝐚𝐥𝐞, we guarantee 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐟𝐨𝐥𝐥𝐨𝐰-𝐮𝐩 and 𝐭𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐭 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧. With all our accreditations and expertise, we can respond quickly to your needs and carry out studies tailored to each project. Our strategic partnerships enrich our services and open up new perspectives for you. Join us in this quest for innovation and let's move forward together in scientific research. 📣 Contact us today to discuss your projects ! 📞 #Biophysium #ClinicalInnovation #Research #Health #Flexibility #CRO #Innovation #Science #Technology #drugdevelopment #Bioscience #Biotech #lifesciences #ClinicalResearch #Clinicaltrial #Research #Health #medicaldevice #cardiovascular #drugdiscovery #nutrition #nutraceutical #echocardiography

8

#IDDI is a proud sponsor of the #DMB Annual Conference taking place in Paris next week! Come meet the experts Erik Falvey, Benoit de Malglaive and join our insightful presentation by Joëlle Périer titled: 📌 The Evolving Role of Clinical Data Managers in Patient-centric Clinical Trials ⏲️ 14:15 - 14:45 CET We look forward to having you there! More: https://lnkd.in/dxZMtFhu #clinicaldatamanagement #patientcentric #biometrics #cro #biostatistics #clinicaldata

40

🩺 Are you looking to improve your understanding and ability to start a #biologic treatment, follow up with the #patient, and evaluate the success of treatment? EUFOREA hosted its first edition of the European Biologics Training Course on 1 March 2024 at the Académie royale de Médecine de Belgique in #brussels with more than 250 attendees worldwide. A hybrid training course designed to increase engagement and understanding of #biologics among healthcare professionals (ENT specialists, pulmonologists, and allergologists) treating patients with uncontrolled type 2 diseases including #asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Atopic Dermatitis (AD). Watch the European Biologics Training Course now and earn your #CME accreditation! 🔗 https://lnkd.in/ejmBkbn4 #eubiologics24 #health #healthcare #healthprofessionals #patients #patientcare #airwaydiseases #chronicdiseases #physicians #trainingcourse #trainingprogram #events2024 #nasalpolyps #asthmaawareness #treatment #ent #nonprofit #euforea #belgium #clinicians #pulmonologist #allergologist #atopicdermatitis #cmecredits

10

[#PressRelease] December 11, 2024 - Kairos Discovery announces €1.5 million grant from Bpifrance. This funding will support regulatory development of its lead drug candidate for the treatment of solid tumors. #oncology #drugdiscovery #deeptech Grateful for the support, especially from Aurélie FAUGIER, Jean-Guillaume Lafay (Norfoalk - Private Equity firm), Stephane Legastelois (33 Californie), Jean-Marie GRUMEL (HARA (Health Angels Rhône Alpes)) and Eglantine Rollet (PULSALYS).

86

9 Comments

📰 French liquid biopsy program delivering personalized Care. A novel program to bring liquid biopsies into clinical care for patients with advanced cancer has been launched in France 🇫🇷. Thanks to AACR Journals for sharing ⤵ https://lnkd.in/dvS9vYQC

97

3 Comments

Last week, the ESMO Precision Medicine Working Group (PMWG) published important recommendations regarding clinical reporting of NGS based molecular results. We have now compared OncoAct WGS reporting with the guidance presented by ESMO and can conclude that OncoAct already follows most of the recommendations! Including: -> Concise clinical summary of the most important findings -> Integration of all different types of molecular data into a single report -> Biological AND clinical annotation of the results https://lnkd.in/dQMAt7FJ https://lnkd.in/e_BWQDMf #innovation #customizedtreatment #moleculardiagnostics #personalizedmedicine #cancerresearch #lifescience

13

1 Comment

[Network] SPUR is™ in the ENABLE MATech repository! We are thrilled to announce that our behavioral diagnostic tool SPUR™ is now officially listed in the MATech repository developed by ENABLE Adherence. The COST Action CA19132 ENABLE (European Network to Advance Best practices & technoLogy on medication adherencE) is a multidisciplinary network comprised of over 100 researchers from 40 partner countries focused on improving medication adherence across Europe. Its mission includes: 1- Raising awareness of adherence-enhancing technologies, 2- Expanding multidisciplinary knowledge, 3- Accelerating the translation of insights into clinical applications, and 4- Promoting the integration of these technologies into healthcare systems. Being part of the MATech repository is an honor, and we are proud to collaborate with the incredible researchers of the ENABLE network. Their mission to give visibility to innovative tools that improve patient adherence and empower healthcare professionals aligns perfectly with our vision at Observia. SPUR™ is designed to enhance patient support and engagement, offering personalized insights into medication adherence behaviors. Thank you Theodosia Charitou, Alexandra Dima, Job van Boven and the ENABLE network for spotlighting solutions like ours. #SPUR #MATech #MedicationAdherence #PatientSupport

28

4 Comments

Tribun Health, a major player in software solutions for digital pathology, has announced its selection among the winners of the i-Nov Wave 11 competition organized by Bpifrance, as part of the France 2030 plan. This competition aims to support the accelerated emergence of innovative companies that are leaders in their field. Tribun Health’s image management software CaloPix® represents a significant advancement in anatomopathology. Tribun Health’s project, “Pathomix®,” strives to broaden diagnostic product offerings, fostering a seamless integration between healthcare services and advancements in research and pharmaceutical development. The project's aim is to empower pathology’s role in precision diagnostics by providing advanced tools for the consolidation, enhancement, and exploitation of real-world data. At the heart of this initiative is the development of an advanced data query module, allowing healthcare facilities to pinpoint specific data for secondary use while adhering to GDPR and HIPAA regulations. #digitalpathology #pathologynews

36

Our wish for 2025 ? Working hand in hand with all the players to close the healthcare gap 🇧🇪 Belgium is a leader in biopharma innovation, with the highest R&D investment per capita in Europe. Yet, Belgian families often miss out on routine tests and treatments available in other EU countries, losing valuable time with loved ones. At Roche, we strongly believe healthcare spending isn’t about doing more but doing better. Together, we can build a smarter, more sustainable system that prioritises prevention, recognises the value of innovation, and puts health at the heart of the new government’s priorities. 🔍 The solutions we wish to bring forward: Healthcare as an Investment: Let's shift the narrative. Healthcare is not just a cost— it's an investment that benefits patients, society and our economy. By prioritising prevention, we can detect diseases earlier, potentially enable recovery, or even prevent them from occurring, therefore contributing to a healthier society. What's in innovation? It's vital to find new treatments and tests, especially where there are none. But let's also celebrate continuous innovations in existing therapy areas that make a difference for patients, enhancing their quality of life. Earlier and faster access to innovative tests and treatments: Belgium is known as a hub for pharmaceutical and biotech innovation but this position is at risk. To maintain our edge, we must evolve the access framework to align with new innovation profiles, and continue to ensure timely patient access to life-changing treatments through clinical trials. ✨ It’s time to turn Belgium’s healthcare potential into reality—for generations to come. We can’t do it alone, let’s work together ! #WeAreRoche #HealthcareInnovation #CloseTheHealthcareGap

64

🔎 𝗔𝗿𝗲 𝘆𝗼𝘂 𝗮 #𝗗𝗧𝘅 𝗼𝗿 #𝗿𝗲𝗺𝗼𝘁𝗲𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝘄𝗮𝗻𝘁𝗶𝗻𝗴 𝘁𝗼 𝗴𝗲𝘁 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗙𝗿𝗮𝗻𝗰𝗲? 🗓 Join us this 10th and 11th of June for a unique workshop with the Délégation au numérique en santé (DNS), Haute Autorité de Santé, France Biotech, and Nextep Health to deeply understand #PECAN and other reimbursement paths, including legislation, regulation, and its key stakeholders. Our deep dive will break down how digital medical products can use their clinical data, review their commercialization strategy, and prepare to succeed in the French healthcare market. Our speakers will provide guidance and advice to understand regulatory frameworks, review and strengthen clinical evidence, and how to be fit for PECAN and other reimbursement paths. Join us to meet: 🎤 Corinne Collignon: As the head of the digital health mission department (Haute Autorité de Santé), she has worked for many years in the medical device evaluation department and will provide her experience around the HAS' expectations (clinical evidence, validation, and evaluation of medical devices). 🎤 Pascal Sellier: As the Vice-Chairman of the National Commission for the Evaluation of Medical Devices and Health Technologies at Haute Autorité de Santé, he represents the voice of patients and users in the French healthcare system. 🎤 Stephane Tholander: Currently he is the coordinator of the digital health commission and vice-president of France Biotech. As a serial entrepreneur and Co-Founder/co-CEO of Agora Health and AppThera, he is focused on innovation in healthcare and facilitating the acceleration and adoption of digital medical devices from all angles. 🎤 Vincent Vercamer: With extensive expertise in regulation and market access, he is currently the project director at the French Ministerial Delegation for Digital Health (DNS/Ministère de la Santé) and works closely with the Agence du numérique en santé, responsible for issues relating to #marketaccess and #PECAN. Additionally, he coordinates the G_NIUS platform, supporting innovators in preparing for their reimbursement applications. 🎤 Helene Viatge: With extensive expertise in medical device development and commercialization in France and Europe and founder of AppThera, a clinician platform supporting the prescription of digital therapeutics and enabling patient access. ✅ 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘯𝘰𝘸 𝘣𝘺 𝘤𝘰𝘯𝘵𝘢𝘤𝘵𝘪𝘯𝘨 𝘰𝘶𝘳 𝘵𝘦𝘢𝘮 𝘰𝘳 𝘴𝘦𝘯𝘥𝘪𝘯𝘨 𝘶𝘴 𝘢 𝘮𝘦𝘴𝘴𝘢𝘨𝘦 𝘷𝘪𝘢 𝘓𝘪𝘯𝘬𝘦𝘥𝘪𝘯 𝘵𝘰 𝘴𝘦𝘤𝘶𝘳𝘦 𝘺𝘰𝘶𝘳 𝘴𝘱𝘰𝘵! #Healthcare #Startups #PECAN #MarketEntry #Regulation #ClinicalEvidence #Workshop #Networking

51

2 Comments

🧬 Are you involved in advanced therapies R&D or related solutions? 🤝 Do you want more visibility to connect with the right investors or partners?   ❗ Then join MEDVIA and BioWin at Advanced Therapies in Belgium, where we focus on cell, gene and other novel therapies 🔥 Register now for a 30% reduction on the ticket fee!   ➡ 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺 📅 𝟭𝟱 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 🗺 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗘𝗰𝗼𝗹𝘆𝘀 𝗩𝗶𝗹𝗹𝗮𝗴𝗲, 𝗡𝗮𝗺𝘂𝗿   WHAT CAN YOU EXPECT? 🧫Plenary session on Belgium’s position in the European ATMP landscape 🧫Debate on major challenges faced by developers of advanced therapies 🧫Presentation of available financing mechanisms 🧫B2B networking & matchmaking 🧫Advanced Therapies Expertise Corner   Sign up to pitch at the event if you have: 🗨️ Project ideas in need of collaboration 🗨️ A track record of joint projects 🗨️ Broad development ideas requiring diverse skills and partners   𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 👉🏽 https://lnkd.in/g8CyafGD 𝗣𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 👉🏽 https://lnkd.in/e2Tm4NDA #ATMP #AdvancedTherapies #celltherapy #genetherapy #NovelTherapies #healthinnovation #healthtech #medtech #biotech #digitalhealth

15

1 Comment

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised close to €61M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia. Meet PDC*line Pharma SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

11

2 Comments

An older but still very relevant publication by Alain Golay about the health-economic impact of non-adherence to treatment. The obvious benefit of good adherence to treatment is an improvement of the condition, but there is so much more to gain. Think about the reduced risk of psycho-social complications, the more cost-effective use of healthcare resources, and the improved health-related quality of life. At Link2Trials we believe that improving adherence to treatment can already start in clinical research. This is why we have developed our ARM services, and why we are involved in the BEAMER project. Keep following Link2Trials and BEAMER to stay up to date as we will post more details about the amazing adherence model the team is developing! https://lnkd.in/e8pryAc8 #beamerproject #patientadherence #patientengagement #clinicalresearch #clinicalcare #clinicaloperations #healthcareinnovations #patientoutcomes #healtheconomics #healthcareprofessionals #healthinsurancepolicy #regulators

10

⭐ Right place, right people, right time, and a wonderful partnership is born ! So grateful to BVI.EU, invest.bw and Université catholique de Louvain for the eagerness to come together in this TechBio venture, gathering science, venture capital, real estate and entrepreneurship.⭐ An AI-driven drug discovery venture builder is born under brand name Quantum BioVenture Studio to foster AI-first biology research approaches in drug discovery. Getting closer to taking humans as a model for humans is therapeutic target identification, the studio will act as a start-up factory leveraging the most advanced machine learning innovations on human multiomics big data. With a focus on rare diseases, and more common diseases related to them through gene regulatory networks, QBVS will work hand in hand with Louvain4Rare coordinated by Prof Olivier Devuyst and TRAIL - TRusted AI Labs co-founded by Prof Benoit Macq. Last but not least, Quantum BioVenture Studio is the first tenant, and at the same time the growth engine, of its mother initiative Quantum Biospace. 🚀 Discover the article release issued this morning in L'Echo. Thanks Olivier Gosset for the sound coverage. Michel Meers | Geoffroy Dumonceau de Bergendal | Pierre de Waha | Xavier Bocquet | Xavier Bastin | Alexia Autenne #techbio #venturestudio #drugdiscovery #ai https://lnkd.in/e68Y-q_S

8

30 % of medicines under development target #rarediseases. In #Belgium, only a limited number of rare disease #treatments are reimbursed. The share is even 15 % lower than six years ago! An alarming situation... See the latest info here: NL: https://lnkd.in/eZvUPWb9 FR: https://lnkd.in/eejtMTaV #zeldzameziekten #maladiesrares #gezondheid #santé #research #onderzoek #recherche #geneesmiddelen #vaccins #médicaments #patiënten #patients #België #Belgique RARE DISEASES ORGANISATION BELGIUM Eva Schoeters Filipo Serra Hanne Wouters Marjan Willaert Patricia van Dijck @eurodis EFPIA - European Federation of Pharmaceutical Industries and Associations #médicamentsorphelins #weesgeneesmiddelen RIZIV-INAMI

44

This Week in VC 🚀 1️⃣ Agomab raised an $89M Series D to advance treatments for fibrotic diseases, with a focus on fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. The Belgian startup attracted investment from Sanofi and Invus. 2️⃣ Armis secured a $200M round at a $4.2B valuation to support its device security solutions, helping organizations manage the risks associated with connected devices. General Catalyst and Alkeon Capital led the round, with participation from Brookfield Technology Partners and Georgian. 3️⃣ Kivu Bioscience launched with a $92M Series A to develop advanced cancer therapies using antibody-drug conjugates that target tumors while reducing side effects. Novo Holdings, Gimv, and Red Tree Venture Capital were key investors. 4️⃣ Read AI landed a $50M Series B to expand its AI bot that summarizes and organizes information from workplace tools like meetings, emails, and Slack. Smash Capital led the round, with Madrona and Goodwater Capital joining. 5️⃣ Sierra raised a $175M round at a $4.5B valuation to develop AI agents that support organizations with complex workflows. Co-founded by former Salesforce co-CEO Bret Taylor, the round was led by Greenoaks Capital, with backing from ICONIQ and Thrive Capital. 🌟 TechCrunch. 💡 Stay tuned with VC Stack for weekly highlights on the latest VC trends and deal news!

1